[Therapy of urinary tract infections with dibekacin]

The use of a new aminoglycosid antibiotic (dibekacin = Orbicin) in the treatment of severe urinary tract infections in a urological clinic is presented. After having given their written informed consent, 50 patients were treated with a dosage of 150-225 mg dibekacin, administered in three single daily doses. From a total of 41 mono-infections, asepsis could be attained in 70,7%, in 17,1% no effect could be observed and in 12,2% it came to a change of bacteria. From a total of 9 mixed infections, asepsis was observed only twice after the end of therapy. 87,5% of the patients reported about a far-reaching improvement or complete disappearance of clinical symptoms. In 2 cases allergic exanthema was observed. The local toleration was good. Disturbances of the otovestibular function were not registered.